The goal of this observational study aims to observe and evaluate the efficacy and safety of a liposomal doxorubicin containing regimen in the postoperative adjuvant treatment of breast cancer patients.
Female, aged 18-75 years;
Primary breast cancer diagnosed histopathologically;
Adjuvant chemotherapy regimens include liposomal doxorubicin;
ECoG PS score: 0-1 points;
Pregnant, lactating patients;
Breast cancer has been found to have distant metastasis;
Those with peripheral nervous system disorders caused by the disease or with a history of significant mental disorders and central nervous system disorders;
Those with severe infection or active peptic ulcer requiring treatment;
Early breast cancer patients who required four cycles of chemotherapy after curative resection of breast cancer
Cohort
Retrospective
Liposomal doxorubicin containing regimen
DrugLiposomal doxorubicin hydrochloride (PLD) 30-40mg/m2 D1 + other drugs (decided by investigators); All patients were treated with 4 cycles.
Cardiac safety
Cardiac ejection fraction
Overall survival
Click on the lead sponsor to view all of their trials.
